BRIEF-Nektar Therapeutics Announces Start Of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin In Moderate-To-Severe Atopic Dermatitis

Nektar Therapeutics

Nektar Therapeutics

NKTR

0.00

July 21 (Reuters) - Nektar Therapeutics NKTR.O:

  • NEKTAR THERAPEUTICS ANNOUNCES START OF PHASE 3 ZENITH AD PROGRAM EVALUATING NOVEL REGULATORY T-CELL BIOLOGIC REZPEGALDESLEUKIN IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

  • NEKTAR THERAPEUTICS - INITIAL PHASE 3 TOPLINE DATA EXPECTED MID-2028; BLA SUBMISSION TARGETED FOR 2029

  • NEKTAR THERAPEUTICS - ZENITH AD PROGRAM TO ENROLL 1,530 PATIENTS ACROSS THREE PHASE 3 STUDIES

Source text: ID:nPn5CXZNQa

Further company coverage: NKTR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.